Live Breaking News & Updates on Scott Bizily|Page 7

Stay updated with breaking news from Scott bizily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Short Interest in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Drops By 11.4%

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) saw a significant decline in short interest in July. As of July 15th, there was short interest totalling 3,110,000 shares, a decline of 11.4% from the June 30th total of 3,510,000 shares. Based on an average daily volume of 589,600 shares, the days-to-cover ratio is currently […] ....

United States , Scott Bizily , Ensign Peak Advisors Inc , Belpointe Asset Management , Lazard Asset Management , D Molecular Therapeutics Inc , Securities Exchange Commission , Denali Advisors , Daiwa Securities Group Inc , Molecular Therapeutics , Get Free Report , Molecular Therapeutics Trading Down , Exchange Commission , Global Investors Lp Viking , Asset Management , Peak Advisors Inc , Daiwa Securities Group , Securities Group , Molecular Therapeutics Daily , 4d Molecular Therapeutics , Nasdaq Fdmt ,

FY2023 EPS Estimates for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Boosted by Chardan Capital

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Free Report) – Chardan Capital lifted their FY2023 EPS estimates for 4D Molecular Therapeutics in a research report issued on Tuesday, July 11th. Chardan Capital analyst G. Livshits now anticipates that the company will earn ($2.66) per share for the year, up from their previous estimate of ($3.13). The […] ....

United States , Scott Bizily , Ensign Peak Advisors Inc , D Molecular Therapeutics Inc , Lazard Asset Management , Belpointe Asset Management , Fred Alger Management , Securities Exchange Commission , Denali Advisors , Molecular Therapeutics , Free Report , Chardan Capital , Molecular Therapeutic , Get Free Report , Molecular Therapeutics Stock Down , Asset Management , Alger Management , Peak Advisors Inc , Global Investors Lp Viking , Exchange Commission , Molecular Therapeutics Daily ,

4D Molecular Therapeutics (NASDAQ:FDMT) Now Covered by Chardan Capital

Chardan Capital began coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research report released on Wednesday, Marketbeat.com reports. The firm issued a buy rating and a $30.00 price target on the stock. Several other equities research analysts have also recently issued reports on FDMT. SVB Securities lowered their price objective […] ....

United States , Scott Bizily , Deutsche Bank , Pricet Rowe Associates Inc , York Mellon Corp , Connor Clark Lunn Investment Management Ltd , Securities Exchange Commission , Charles Schwab Investment Management Inc , D Molecular Therapeutics Inc , Chardan Capital , Molecular Therapeutics , Free Report , Moderate Buy , Global Investors Lp Viking , Exchange Commission , Lunn Investment Management , New York Mellon Corp , Schwab Investment Management , Molecular Therapeutics Daily ,

4D Molecular Therapeutics (NASDAQ:FDMT) Coverage Initiated at Chardan Capital

Chardan Capital started coverage on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a research report issued to clients and investors on Wednesday, The Fly reports. The brokerage set a “buy” rating on the stock. A number of other analysts have also weighed in on FDMT. HC Wainwright restated a “buy” rating and […] ....

United States , Scott Bizily , Jacob Chacko , Millennium Management , D Molecular Therapeutics Inc , D Molecular Therapeutics Company Profile , Norges Bank , Chardan Capital , Molecular Therapeutics , Free Report , Molecular Therapeutics Stock Down , Director Jacob Chacko , Street Corp , Molecular Therapeutics Company , Molecular Therapeutics Daily ,